CCXI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the historical short interest of Chemocentryx Inc, as measured by the Short Percentage Of Float.
This the Institutional Ownership History of Chemocentryx IncPeter Lynch prefers to buy companies with low institutional ownership.
This is the historical insider ownership of Chemocentryx Inc. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case.
|Holder||Position||Shares||% of Shares |
|Dr. Thomas J. Schall, PhD||President and CEO||2,148,667||4.96%||2014-05-01|
|Dr. Petrus (Pirow) Bekker, M.D.,PhD||SVP of Medical & Clinical||53,594||0.12%||2013-08-07|
|Dr. Roger C. Lucas, PhD||Director||40,000||less than 0.1%||2013-08-05|
|Dr. Juan C. Jaen, PhD||SVP, Drug Discovery & CSO||30,000||less than 0.1%||2013-03-07|
|Dr. Markus J. Cappel, PhD||Chief Bus. Officer & Treasurer||12,500||less than 0.1%||2013-03-05|
|Dr. Joseph M. Feczko||Director||10,000||less than 0.1%||2013-09-13|
|Mr. Geoffrey M. Parker||Director||9,600||less than 0.1%||2013-12-06|
|Holder||Shares||Report Date||% of Shares |
|% of Total |
|VA CollegeAmerica Small Cap World||3,467,240||2014-12-31||8.00||0.10||23,681,249|
|Capital World Investors||3,426,800||2014-09-30||7.91||0.00||15,421,000|
|Balyasny Asset Management LLC||2,764,227||2014-09-30||6.38||0.10||12,439,000|
|Wasatch Advisors Inc.||2,543,034||2014-09-30||5.87||0.12||11,444,000|
|Franklin Advisers, Inc.||1,824,797||2014-09-30||4.21||0.01||8,212,000|
|Westfield Capital Management Company, LP||1,366,793||2014-09-30||3.15||0.04||6,151,000|
|Wasatch Small Cap Growth Fund||1,357,191||2014-09-30||3.13||0.27||6,107,360|
|Franklin Biotechnology Discovery||1,194,757||2014-10-31||2.76||0.26||6,714,534|
|BlackRock Fund Advisors||1,188,581||2014-09-30||2.74||0.00||5,349,000|